Etanercept Formulations Stabilized with Sodium Chloride
AssigneeCoherus Biosciences, Inc.
InventorsMark MANNING, Brian MURPHY
Life of this patent
Estimating the term…
Abstract
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Claims20
A stable aqueous etanercept formulation comprising about 25 to about 75 mg/ml of etanercept, wherein the etanercept is stabilized by a stabilizing component having about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and one or more amino acids selected from the group consisting of L-serine, sodium glutamic acid, alanine, glycine, and lysine, wherein the stable aqueous etanercept formulation is free of arginine.
A method of treating a subject in need of treatment by injection of etanercept comprising administering to the subject a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, wherein the etanercept is stabilized by a stabilizing component having about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and one or more amino acids selected from the group consisting of L-serine, sodium glutamic acid, alanine, glycine, and lysine, wherein the stable aqueous etanercept composition is free of arginine.
A vial, syringe, or injector pen containing a stable aqueous etanercept composition comprising 25 to 75 mg/ml etanercept, wherein the etanercept is stabilized by an aqueous buffer and a stabilizing component having about 3 to 5 wt. % of sucrose, sodium chloride, sodium citrate, and one or more amino acids selected from the group consisting of L-serine, sodium glutamic acid, alanine, glycine, and lysine, wherein the stable aqueous etanercept composition is free of arginine, wherein the stable aqueous etanercept composition has a pH of about 6.0 to about 6.6.
Dependencies are inferred from the claim text.